东阳光药尾盘涨超4% 首仿盐酸芬戈莫德胶囊获国家药监局批准上市

Core Viewpoint - Dongyangguang Pharmaceutical (600673) has seen a significant stock increase of over 4% following the approval of its first oral immunosuppressant, Fingo Mod, by the National Medical Products Administration of China, marking a milestone for the company and the industry [1] Company Summary - Dongyangguang Pharmaceutical's stock rose by 4.38%, reaching HKD 47.7, with a trading volume of HKD 14.98 million [1] - The approval of Fingo Mod capsules represents the company's first generic drug and the first oral medication for multiple sclerosis (MS) in China [1] - Fingo Mod, developed by Novartis and Mitsubishi Tanabe Pharma, has generated over USD 3 billion in global sales annually from 2016 to 2020 [1] - The company is recognized as the first stock in China to achieve absorption and merger, establishing an integrated platform for research, production, and sales of innovative drugs [1] Industry Summary - The research direction of Dongyangguang Pharmaceutical focuses on three major areas: anti-infection, chronic diseases (metabolism), and oncology, with a rich pipeline of research and development [1] - The company has seen rapid growth in its listed products, indicating a promising future for global innovation in the pharmaceutical sector [1] - According to a report from China Merchants Securities, the company’s innovative pipeline development is highly regarded, leading to a strong buy recommendation for investors [1]